Navigation Links
Care-Tech Laboratories Agrees to Stop Making, Selling and Distributing Unapproved Antimicrobial Products
Date:9/8/2009

WASHINGTON, Sept. 8 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that St. Louis-based Care-Tech Laboratories Inc. and its principal officers, John C. Brereton and Sherry L. Brereton, have signed a consent decree, agreeing to stop the illegal manufacture, marketing, and distribution of over-the-counter (OTC) antimicrobial drugs used to treat and prevent infection.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Inspectors found that Care-Tech violated numerous provisions of the FDA's current good manufacturing practice (cGMP) regulations that direct how antimicrobial drugs are made. Additionally, the products do not conform to any applicable regulations for OTC drug products and have not undergone an FDA review, and therefore are considered unapproved drug products.

Under the terms of the consent decree, Care-Tech may not resume manufacturing and distribution of the drugs until it corrects these and other violations.

"The FDA is concerned about Care-Tech's products because they lack FDA approval, do not conform to any applicable over-the-counter drug monograph, and are not appropriately manufactured," said Deborah Autor, director of the FDA's Office of Compliance, Center for Drug Evaluation and Research. "Companies have an obligation to consumers to ensure that their products are safe, effective, and high quality, and the FDA recommends that Care-Tech's customers seek alternative products."

Care-Tech products are sold online and through telephone orders to hospitals, nursing homes and other health care facilities. They are not sold in retail stores. The FDA is not aware of any reports of injury or illness related to the use of these products. Consumers should contact Care-Tech at 1-800-325-9681 to return products in their possession, which include:

Barri-Care

Care-Creme

Caricia Care

CC-500

Clinical Care

Consept

Formula Magic

Humatrix

Loving Lather

Loving Lather II

Loving Lotion

Orchid Fresh II

Satin

Tech 2000

Techni-Care

Urban Skin

Health care professionals and consumers may report serious adverse events (side effects) or quality problems for these or any products to the FDA's MedWatch Adverse Event Reporting program, online, or by regular mail, fax or phone.

For more information:

Facts About Current Good Manufacturing Practices (cGMPs)

Media Inquiries: Christopher Kelly, 301-796-4676, christopher.kelly@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
2. Breckenridge Pharmaceutical Enters Agreement with Orit Laboratories (West Caldwell, NJ) to Market Ergocalciferol (Vitamin D) Capsules
3. AUDIO from Medialink and Forest Laboratories: Dangers of Switching Medications
4. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Imitrex(R) Tablets
5. Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
7. Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
10. Leading health organizations launch new accreditation process for laboratories across Africa
11. IDEXX Laboratories Announces Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 23, 2017 , ... News Advisory/Interview Opportunity , After six years of advocacy, ... in Europe for public health and the environment and is calling on the United ... and the overwhelming support of European citizens, the European Union (EU) will, beginning next ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest multi-specialty ... payment system, to expand its focus on patient care by providing an advanced ... , “At Ogden Clinic, we are working to become a different type of ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex ... of “Profiling protein expression in circulating tumor cells using microfluidic western blotting” in ... of the Vortex technology to capture CTCs and a microfluidic single-CTC ...
(Date:3/22/2017)... ... 22, 2017 , ... Sam & Associates Insurance Agency, a ... related services to residents of the region, is embarking on a charity effort ... wild lands. , Endangered Species International is committed to ending the anthropogenic trends ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... consuming and frustrating and this tool bypasses that. Healthcare facilities across the ... an opportunity to offer their clients and hospitals, across the country, an efficient ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... NEW YORK , March 22, 2017 ... ... cannabis market was worth an estimated $6.6 billion in 2016, and ... of 16% or reaching more than $24 billion by 2025. The ... 2025, or growing from $4.7 billion in 2016, to an estimated ...
(Date:3/22/2017)... 22, 2017 FinancialBuzz.com News Commentary ... rapidly due to the significant development and innovation in ... Market Research, the global electrophysiology market was worth $3.42 ... billion by 2022, with a GAGR of 13.4%. Electrophysiology ... diagnose abnormal heartbeats or arrhythmia. The report indicates that ...
(Date:3/22/2017)... MAPLE GROVE, Minn. , March 22, 2017   ... of Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and ... (clomipramine hydrochloride) Capsules USP. The clomipramine ... for the 12 months ending December 2016, according to IMS ... ...
Breaking Medicine Technology: